RBC Capital Reaffirms Their Hold Rating on Banco Santander (BNC)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
According to TipRanks, Toms is a 5-star analyst with an average return of 17.9% and a 69.23% success rate. Toms covers the Financial sector, focusing on stocks such as Banco Bilbao Vizcaya Argentaria, Close Brothers Group, and HSBC Holdings.
Banco Santander has an analyst consensus of Strong Buy, with a price target consensus of p650.83, which is a 4.64% upside from current levels. In a report released today, J.P. Morgan also maintained a Hold rating on the stock with a €7.50 price target.
The company has a one-year high of p651.00 and a one-year low of p326.50. Currently, Banco Santander has an average volume of 5.31M.
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is neutral on the stock.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)
Abbott Laboratories (NYSE:ABT) ranks among the . RBC Capital maintained its Outperform rating on Abbott Laboratories (NYSE:ABT) on July 15 and raised its price target from $145 to $147. The firm pointed to Abbott's strong single-digit revenue and double-digit EPS growth potential as examples of its ability to provide top-tier financial growth in the medical technology industry. According to RBC Capital's intra-quarter checks, Abbott Laboratories (NYSE:ABT) maintains positive healthcare utilization in Q2. Moreover, Abbott's diabetes brand, which has been attracting a lot of investor interest, was one of the several growth catalysts mentioned in the firm's report. The less elective nature of Abbott's medical device portfolio was also mentioned by RBC as a benefit. RBC Capital's sustained belief in Abbott Laboratories (NYSE:ABT) as the best-performing large cap in its coverage year-to-date is bolstered by other positives such as business momentum in diabetes care, favorable trends in diagnostics, stability in nutrition, and strength in established pharmaceuticals. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio
Business Insider
28 minutes ago
- Business Insider
Suncorp Group (SNMYF) Gets a Hold from Citi
In a report released today, Nigel Pittaway from Citi maintained a Hold rating on Suncorp Group, with a price target of A$22.40. The company's shares closed last Friday at $10.83. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Pittaway covers the Financial sector, focusing on stocks such as ASX , Insurance Australia Group Limited, and AMP . According to TipRanks, Pittaway has an average return of 3.4% and a 56.50% success rate on recommended stocks. In addition to Citi, Suncorp Group also received a Hold from TR | OpenAI – 4o's Wesley Roofguard in a report issued on July 26. However, on July 25, Morgan Stanley maintained a Buy rating on Suncorp Group (Other OTC: SNMYF). The company has a one-year high of $17.99 and a one-year low of $10.37. Currently, Suncorp Group has an average volume of 531.
Business Insider
an hour ago
- Business Insider
UBS Keeps Their Buy Rating on Ampol Limited (CTXAF)
UBS analyst Tom Allen maintained a Buy rating on Ampol Limited today and set a price target of A$31.50. The company's shares closed last Friday at $16.30. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Allen covers the Energy sector, focusing on stocks such as Santos Limited, Origin Energy Limited, and Beach Energy . According to TipRanks, Allen has an average return of 9.1% and a 61.84% success rate on recommended stocks. In addition to UBS, Ampol Limited also received a Buy from Morgan Stanley's Robert Koh in a report issued on July 24. However, on the same day, J.P. Morgan maintained a Hold rating on Ampol Limited (Other OTC: CTXAF). The company has a one-year high of $24.02 and a one-year low of $14.43. Currently, Ampol Limited has an average volume of 750.
